Lumretuzumab
- Generic Name
- Lumretuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1448327-63-6
- Unique Ingredient Identifier
- Y6M3205516
- Background
Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 66
- Registration Number
- NCT01918254
- Locations
- 🇫🇷
Institut Curie; Oncologie Medicale, Paris, France
🇩🇪Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany
🇪🇸Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath